SCHEDULE: Farallon Capital Discloses 9.7% Stake in Tango Therapeutics

Farallon Capital Management and its affiliates have reported a collective beneficial ownership of 9.7% of Tango Therapeutics' common stock.

Summary

• Farallon Capital Partners, L.P. and its affiliated entities, collectively referred to as the 'Farallon Funds,' along with their general partners and individual managing members, have filed an Amendment No. 2 to Schedule 13G.
• The filing reports beneficial ownership of 10,757,000 shares of Tango Therapeutics, Inc. common stock, representing 9.7% of the class.
• The Farallon Funds directly hold varying amounts of shares, with Farallon Capital Offshore Investors II, L.P. holding the largest individual stake among the funds at 4,421,621 shares (4%).
• Farallon Partners, L.L.C., as the general partner for most Farallon Funds, is deemed to beneficially own 10,331,579 shares (9.3%).
• Eighteen individual managing members and senior managing members of Farallon's general partners are each deemed to beneficially own 10,757,000 shares (9.7%) due to their investment discretion.
• The Reporting Persons certified that the securities were not acquired or held for the purpose of changing or influencing control of Tango Therapeutics, Inc., other than activities solely in connection with a nomination under Rule 14a-11.
• The Farallon General Partner, FCIP V General Partner, F5MI General Partner, and the Farallon Individual Reporting Persons disclaim beneficial ownership of any such shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's operational or financial performance.

Risks

• The Reporting Persons disclaim any beneficial ownership of the shares held by the Farallon Funds, which is a standard legal disclaimer for control persons.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Tango Therapeutics, Inc. or the reporting entities regarding the issuer's future performance.

Industry Context

This filing indicates a significant institutional investment in Tango Therapeutics, a biotechnology company. Such a substantial stake by a prominent hedge fund like Farallon Capital can signal confidence in the company's long-term prospects or its strategic value within the biotechnology sector, potentially attracting further investor attention.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a significant investment firm like Farallon Capital could be viewed positively, potentially signaling confidence in the company's value or future prospects.
• Company Management: A large institutional investor may exert influence through engagement, although the filing states the shares were not acquired for the purpose of changing or influencing control, other than potential nominations under Rule 14a-11.

Key Dates

Keywords

Tango Therapeutics, Farallon Capital, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake